Avoro Capital Advisors Reduces $218M in Amicus Therapeutics Inc ($FOLD)

Avoro Capital Advisors has completely exited its position in Amicus Therapeutics Inc (NGM:FOLD), according to its recent 13F filing with the SEC. The fund sold all 15.03 million shares it previously held, marking a full divestment of its stake in the biotechnology company.

What Changed in Avoro Capital Advisors' Amicus Therapeutics Position

Avoro Capital Advisors' decision to cut its position in Amicus Therapeutics was significant, as it previously held 15.03 million shares. The fund's exit represents a 100% reduction, bringing its stake to zero shares as of the reporting period.

Other Institutional Activity in Amicus Therapeutics

Other notable institutional investors have shown varying levels of activity in Amicus Therapeutics. BlackRock, Inc. increased its holdings by 1.35 million shares, bringing its total to approximately 33.88 million shares valued at $489.9 million. UBS Group AG also boosted its stake significantly, adding over 10 million shares to reach 15.96 million shares worth $230.75 million. Vanguard Capital Management LLC established a new position with 14.02 million shares, while Pentwater Capital Management LP raised its holdings by 2.5 million shares to a total of 14 million shares. On the other hand, State Street Corp reduced its position by nearly 1.94 million shares, ending with about 12.89 million shares.

Amicus Therapeutics Stock Snapshot

Shares of Amicus Therapeutics (NGM:FOLD) traded near $14.49, just shy of its 52-week high of $14.5. The company has a market cap of approximately $4.55 billion and a forward P/E ratio of 17.7. Amicus Therapeutics exhibits a beta of 0.481, indicating lower volatility compared to the market. The stock's 50-day moving average stands at $14.403, with the 200-day moving average at $10.88025. The company's current ratio is 2.843, and its quick ratio is 1.719, reflecting its liquidity position. However, the debt-to-equity ratio is relatively high at 161.304.

Recent Earnings

Amicus Therapeutics reported revenue of $634.21 million with a growth rate of 23.7%. Despite this, the company posted a net margin of -4.28% and a return on equity of -11.58%, indicating ongoing profitability challenges. The company's next earnings date has not been provided.

Insider Buying and Selling at Amicus Therapeutics Inc

Several insiders at Amicus Therapeutics have sold shares recently. On April 27, 2026, President and CEO Bradley Campbell sold 1,008,680 shares at $14.5 per share. Other executives, including Chief Legal Officer Ellen Rosenberg and Chief People Officer David Michael Clark, also sold significant amounts of shares on the same day.

Analysts Set New Price Targets

Analysts have been adjusting their outlook on Amicus Therapeutics. On January 22, 2026, Jefferies downgraded the stock to a hold rating with a price target of $14.5. Similarly, Leerink Partners and Citigroup issued hold ratings with the same target price in late 2025. The consensus among analysts is a hold recommendation, with a mean price target of $14.5 based on five opinions.

About Amicus Therapeutics

Amicus Therapeutics Inc, headquartered in Princeton, New Jersey, is a biotechnology firm focused on developing treatments for rare diseases. The company offers innovative therapies such as Galafold for Fabry disease and Pombiliti + Opfolda for late-onset Pompe disease. With around 511 employees, Amicus collaborates with companies like GlaxoSmithKline and Dimerix Limited to enhance its product offerings.

Bottom Line

Avoro Capital Advisors' complete exit from Amicus Therapeutics is a notable development in the company's institutional ownership landscape. Investors often track such changes to gauge confidence levels in the company's future. This 13F filing is backward-looking, reflecting holdings as of the reporting period and may not represent the current position.